Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.71 |
| ▸ | MEN1 | O00255 | 7/20 | 0.71 |
| ▸ | TGM2 | P21980 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | NAMPT | P43490 | 1/20 | 0.59 |
| ▸ | MITF | O75030 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | MYOC | Q99972 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6302157 | 0.83 | MEN1 (1.00) | KMT2AMEN1TGM2NPC1MAPT | |
| SCHEMBL1177730 | 0.83 | MEN1 (1.00) | KMT2AMEN1TGM2NPC1MAPT | |
| SCHEMBL152811 | 0.82 | KMT2A (0.74) | KMT2AMEN1TGM2NPC1MAPT | |
| SCHEMBL5817153 | 0.82 | KMT2A (0.74) | KMT2AMEN1TGM2NPC1MAPT | |
| SCHEMBL6631700 | 0.80 | KMT2A (0.71) | KMT2AMEN1TGM2NPC1MAPT | |
| SCHEMBL8848976 | 0.80 | KMT2A (0.71) | KMT2AMEN1TGM2NPC1MAPT | |
| SCHEMBL1102071 | 0.80 | KMT2A (0.71) | KMT2AMEN1TGM2NPC1MAPT | |
| SCHEMBL11154886 | 0.80 | NPC1 (0.48) | KMT2AMEN1NPC1MAPTRAB9A | |
| SCHEMBL9018657 | 0.80 | MEN1 (0.71) | KMT2AMEN1TGM2NPC1MAPT | |
| SCHEMBL4588400 | 0.80 | KMT2A (0.71) | KMT2AMEN1TGM2NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339537-A1 | NOVEL COMPOUND AS INHIBITOR AGAINST BINDING OF PF34 PROTEIN TO NEDD4-1 PROTEIN AND USE THEREOF | ENHANCEDBIO, INC. (KR) | 2020-10-29 | — | — | US | disclosed |
| WO-2019243825-A1 | SMALL MOLECULE MODULATORS OF HUMAN STING, CONJUGATES AND THERAPEUTIC APPLICATIONS | CURADEV PHARMA LIMITED (GB) | 2019-12-26 | — | — | WO | disclosed |
| CN-104995184-B | As the one inducer of 2,3 xylylenimine 1 of BTK kinase inhibitors and containing such pharmaceutical compositions | 晶体基因技术株式会社 | 2018-01-02 | — | — | CN | disclosed |
| US-9193713-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2015-11-24 | — | — | US | disclosed |
| EP-2851366-A1 | Compounds as cannabinoid receptor ligands | Abbvie Inc. (US) | 2015-03-25 | — | — | EP | disclosed |
| EP-2630141-A1 | CATHEPSIN S INHIBITOR COMPOUNDS | Eli Lilly and Company (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8492371-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8227468-B2 | Cathepsin S inhibitor compounds | ELI LILLY AND COMPANY (US) | 2012-07-24 | — | — | US | disclosed |
| WO-2012054315-A1 | CATHEPSIN S INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2012-04-26 | — | — | WO | disclosed |
| US-20120095020-A1 | Cathepsin S Inhibitor Compounds | ELI LILLY AND COMPANY (US) | 2012-04-19 | — | — | US | disclosed |
| EP-2219629-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20090105306-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-04-23 | — | — | US | disclosed |
| WO-2009048936-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-04-16 | — | — | WO | disclosed |
| EP-1183246-A1 | TETRAZOLINONE DERIVATIVES | NIHON BAYER AGROCHEM K.K. (JP) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000071527-A1 | TETRAZOLINONE DERIVATIVES | NIHON BAYER AGROCHEM K.K. (DE) | 2000-11-30 | — | — | WO | disclosed |
| EP-0241559-B1 | OXAZOLIDINEDIONE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND HERBICIDES CONTAINING THE SAME | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1991-10-30 | — | — | EP | disclosed |
| US-4983751-A | Chemical intermediates | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1991-01-08 | — | — | US | disclosed |
| US-4818272-A | NONPHYTOTOXICITY FOR CROPS HELICAL STREAMS | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1989-04-04 | — | — | US | disclosed |
| EP-0241559-A1 | OXAZOLIDINEDIONE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND HERBICIDES CONTAINING THE SAME | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1987-10-21 | — | — | EP | disclosed |
| US-4467092-A | Carbamates and thiocarbamates of 3-hydroxy-4-pyridyloxyphenoxy alkanoic acid esters | ZOECON CORPORATION (US) | 1984-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105306-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | KMT2A 2386/4885MEN1 2567/4885TGM2 4357/4885 |
| US-20120095020-A1 | Cathepsin S Inhibitor Compounds | CTSS, CTSZ, CTSV | KMT2A 3912/4885MEN1 2189/4885TGM2 1638/4885 |
| US-20200339537-A1 | NOVEL COMPOUND AS INHIBITOR AGAINST BINDING OF PF34 PROTEIN TO NEDD4-1 PROTEIN AND USE THEREOF | NEDD4, PFDN1, PF4 | KMT2A 3515/4885MEN1 1975/4885TGM2 4111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.